- Home
- PNW vs MRNA Comparison
PNW vs MRNA Comparison
Compare PNW & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PNW
- MRNA
- Stock Information
- Founded
- PNW 1985
- MRNA 2010
- Country
- PNW United States
- MRNA United States
- Employees
- PNW N/A
- MRNA N/A
- Industry
- PNW Electric Utilities: Central
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PNW Utilities
- MRNA Health Care
- Exchange
- PNW Nasdaq
- MRNA Nasdaq
- Market Cap
- PNW 10.8B
- MRNA 10.9B
- IPO Year
- PNW N/A
- MRNA 2018
- Fundamental
- Price
- PNW $88.18
- MRNA $23.51
- Analyst Decision
- PNW Buy
- MRNA Hold
- Analyst Count
- PNW 11
- MRNA 19
- Target Price
- PNW $96.45
- MRNA $43.50
- AVG Volume (30 Days)
- PNW 901.7K
- MRNA 11.1M
- Earning Date
- PNW 11-05-2025
- MRNA 11-06-2025
- Dividend Yield
- PNW 4.06%
- MRNA N/A
- EPS Growth
- PNW N/A
- MRNA N/A
- EPS
- PNW 4.81
- MRNA N/A
- Revenue
- PNW $5,255,240,000.00
- MRNA $3,078,000,000.00
- Revenue This Year
- PNW $4.14
- MRNA N/A
- Revenue Next Year
- PNW $5.56
- MRNA $10.17
- P/E Ratio
- PNW $18.33
- MRNA N/A
- Revenue Growth
- PNW 7.47
- MRNA N/A
- 52 Week Low
- PNW $81.47
- MRNA $23.15
- 52 Week High
- PNW $96.50
- MRNA $75.37
- Technical
- Relative Strength Index (RSI)
- PNW 40.26
- MRNA 36.83
- Support Level
- PNW $87.00
- MRNA $24.21
- Resistance Level
- PNW $88.52
- MRNA $25.90
- Average True Range (ATR)
- PNW 1.02
- MRNA 1.19
- MACD
- PNW -0.17
- MRNA 0.08
- Stochastic Oscillator
- PNW 30.97
- MRNA 8.17
About PNW Pinnacle West Capital Corporation
Pinnacle West is a holding company whose principal subsidiary is Arizona Public Service, a vertically integrated electric utility serving approximately 1.4 million customers across a 35,000-square-mile territory in central Arizona, including the Phoenix area. APS owns or leases more than 6 gigawatts of power generation capacity, including a 29% ownership stake in one of the largest nuclear plants in the US, Palo Verde. Half of the electricity that APS supplies to customers comes from clean energy sources, including nuclear.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.